Compare moats

Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K.

source: sec.gov

The FY2025 10-K (fiscal year ended August 29, 2025) documents design-in niches but no durable excess return. In favour: the Competition section says some large rivals 'tend to have limited customization and service capabilities and are generally focused on higher-volume memory, storage, or compute products that are manufactured to industry-standard specifications'. It says the company's 'close collaboration with customers, customer-specific designs, long-lifecycle solutions, superior products and proprietary supply chain services create significant customer loyalty that may provide an advantage when competing against large international companies'. Against: the same filing says many competitors have 'substantially greater financial, technical, marketing, distribution and other resources' and 'lower cost structures'. Sales are made 'primarily pursuant to customer purchase orders and are not based on long-term supply agreements', and 'customers are not obligated to purchase our products even if we achieve a design win'. Large customers 'have exerted' pressure for price concessions, and the ten largest were 66% of fiscal 2025 net sales. GAAP operating income was 0.6%, 1.6% and 4.2% of net sales in fiscal 2023, 2024 and 2025, and fiscal 2024 had a net loss from continuing operations of $41.8 million. The 10-Q for the quarter ended May 29, 2026 (filed 2026-07-07, https://www.sec.gov/Archives/edgar/data/1616533/000161653326000043/peng-20260529.htm) adds that Advanced Computing nine-month sales fell 20.6%, reflecting 'both the ongoing Penguin Edge wind down and hyperscale hardware sales in 2025 that did not recur in 2026'. The filing's own advantage claim is hedged ('may provide an advantage'): design-in niches exist, but the 10-K shows no durable excess return.

source: sec.gov

Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly.

source: sec.gov

The strongest candidate moat source in the 10-K is design-in and qualification, a switching-cost argument, and the filing limits it too far to count. The risk factors say 'Our products are often incorporated into customers' systems at the design stage', and many specialty products 'are specifically designed for our OEM customers' systems or products'. But qualification is 'both product-specific and platform-specific', so a design win covers one platform. The filing notes that customers 'sometimes require us to re-qualify our products' for new platforms, which 'can be time-consuming and cause reductions in our net sales', so each new platform reopens the socket. It also says 'customers are not obligated to purchase our products even if we achieve a design win', and warns that OEMs designing in 'standardized or commodity components' could reduce demand for its 'higher priced specialized or customized solutions'. Scale is ruled out because the filing says many competitors have lower cost structures. Patents are ruled out as a durable source. The company holds about 1,650 of them and calls intellectual property 'an important aspect of our business', but it says its patents 'do not cover all of our technologies' and that competitors 'may design around our patented technologies'. It also says some products are 'built around mature industry standards and have less patent protection', so 'we cannot prevent our competitors from reverse-engineering and duplicating those products'.

source: sec.gov

Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K.

source: sec.gov

The 10-K claims no share figure or rank in any segment. It says 'Our businesses compete with numerous global and local companies'. Its HPC and AI business 'competes primarily with global manufacturers of HPC and AI products and services'. For fault-tolerant solutions it says 'we primarily compete with manufacturers of enterprise servers and industrial computers'. Its memory business competes 'against memory module providers and, to a lesser extent, large semiconductor manufacturers'. The risk factors warn that larger competitors 'may be able to respond better to new or emerging technologies, such as generative AI'. Against that, the company's stated edge is customization and service, where it says some large rivals 'tend to have limited customization and service capabilities'. Its leadership language is self-description without share figures: Cree LED 'has been a leader in LED lighting technology', Stratus Technologies is 'a global leader in simplified, protected and autonomous computing platforms and services', and the memory business is 'a primary supplier of longer-lifecycle solutions to OEM customers'. A specialist that claims no rank and faces many larger, lower-cost rivals, while neither leading nor clearly trailing in its niches, is parity.

source: sec.gov

Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong.

source: sec.gov

The FY2025 10-K describes price as set by customers and the market. It says its large customers 'are able to exert, have exerted and we expect will continue to exert, pressure on us to make concessions on price and on terms and conditions'. It says 'The markets for our Integrated Memory products have historically been characterized by declines in average selling prices', and that 'Competitive pressure has led in the past and may continue to lead to intensified price competition resulting in lower net sales and lower profit margins'. Gross margin held in a narrow band: 28.8% in fiscal 2023, 29.1% in fiscal 2024 and 28.8% in fiscal 2025. The filing attributes each move to mix, for example higher-margin Advanced Computing service revenue in 2024, not to pricing. The 10-Q for the quarter ended May 29, 2026 (filed 2026-07-07, https://www.sec.gov/Archives/edgar/data/1616533/000161653326000043/peng-20260529.htm) reports gross margin of 27.8% versus 29.3% a year earlier (27.7% versus 28.9% for nine months), which it attributes to the Penguin Edge wind-down and sales mix. Third-quarter Integrated Memory sales rose 111.4% (75.6% for nine months) as 'accelerating AI-driven demand drove favorable pricing and increased volume', and the 10-Q says that business has 'gross margins which are lower than the Company average'.

source: sec.gov

Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect.

Downstream integrator. Per the 10-K it buys memory from Samsung, Micron, SK hynix and Kioxia and processors from Intel and AMD, and turns them into specialty memory modules and managed AI/HPC clusters for OEM, enterprise, government and cloud customers.

• Mounjaro (tirzepatide) Top 3 · Deep source: sec.gov
• Verzenio (abemaciclib) Leader · Moderate source: living.tech
• Zepbound (tirzepatide) Leader · Deep source: sec.gov

• AI and HPC infrastructure (OriginAI, ICE ClusterWare) Unknown · Low source: sec.gov
• Cree LED chips and components (XLamp, J Series, high-brightness SMD) Unknown · Low source: sec.gov
• SMART Modular specialty memory and storage (DRAM modules, Zefr, CXL, flash/SSD) Niche · Moderate source: sec.gov
• Stratus fault-tolerant computing (ztC Endurance, ftServer, ztC Edge, everRun) Niche · Low source: sec.gov

Editorial prior, not backtested.

see exactly how it voted →

Editorial prior, not backtested.

see exactly how it voted →